Browsing ICR Divisions by author "Taprogge, Jan"
Now showing items 1-12 of 12
-
A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease.
Taprogge, J; Gape, PMD; Carnegie-Peake, L; Murray, I; Gear, JI; et al. (MARY ANN LIEBERT, INC, 2021-12-01)Background: Patients with Graves' disease are commonly treated with radioiodine. There remains controversy over whether the aim of treatment should be to achieve euthyroidism or hypothyroidism, and whether treatments should ... -
Adjustment of the iodine ICRP population pharmacokinetic model for the use in thyroid cancer patients after thyroidectomy.
Taprogge, J; Carnegie-Peake, L; Murray, I; Gear, JI; Flux, GD (IOP Publishing Ltd, 2021-11-11)Biokinetic models developed for healthy humans are not appropriate to describe biokinetics in thyroid cancer patients following thyroidectomy. The aim of this study was to adjust the population model for iodine proposed ... -
Characterisation of the attenuation properties of 3D-printed tungsten for use in gamma camera collimation.
Gear, JI; Taprogge, J; White, O; Flux, GD (SPRINGER, 2019-01-07)BACKGROUND: The aim of this work was to characterise the attenuation properties of 3D-printed tungsten and to assess the feasibility for its use in gamma camera collimator manufacture. METHOD: 3D-printed tungsten disks ... -
Compartmental Model for 223Ra-Dichloride in Patients With Metastatic Bone Disease From Castration-Resistant Prostate Cancer.
Taprogge, J; Murray, I; Gear, J; Chittenden, SJ; Parker, CC; et al. (ELSEVIER SCIENCE INC, 2018-06-04)PURPOSE: 223Ra-Dichloride is used for treatment of patients with metastatic bone disease from castration-resistant prostate cancer. The uptake and mechanism of action of 223Ra-Dichloride is not well understood. The aim of ... -
Initial results of the INSPIRE clinical trial -Investigating radiation dosimetry for differentiated thyroid cancer patients
Taprogge, J; Rushforth, D; Gear, J; Murray, I; Wong, KH; et al. -
Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project.
Taprogge, J; Vergara-Gil, A; Leek, F; Abreu, C; Vávrová, L; et al. (SPRINGER, 2023-09-01)PURPOSE: Dosimetry is rarely performed for the treatment of differentiated thyroid cancer patients with Na[131I]I (radioiodine), and information regarding absorbed doses delivered is limited. Collection of dosimetry data ... -
Quantification and dosimetry of small volumes including associated uncertainty estimation.
Carnegie-Peake, L; Taprogge, J; Murray, I; Flux, GD; Gear, J (SPRINGER, 2022-12-13)BACKGROUND: Accurate quantification of radioactivity in a source of interest relies on accurate registration between SPECT and anatomical images, and appropriate correction of partial volume effects (PVEs). For small ... -
Radiation protection aspects for alpha therapies.
Craig, AJ; Taprogge, J; Flux, GD; Murray, I (EDIZIONI MINERVA MEDICA, 2023-03-01)The use of alpha emitting radiotherapeutics is increasing, with further growth expected due to a number of clinical trials currently running involving new alpha emitters. However, literature concerning radiation safety ... -
Recommendations for Multicentre Clinical Trials Involving Dosimetry for Molecular Radiotherapy.
Taprogge, J; Wadsley, J; Miles, E; Flux, GD (ELSEVIER SCIENCE LONDON, 2021-02-01)Multicentre clinical trials involving a dosimetry component are becoming more prevalent in molecular radiotherapy and are essential to generate the evidence to support individualised approaches to treatment planning and ... -
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.
Wadsley, J; Ainsworth, G; Coulson, AB; Garcez, K; Moss, L; et al. (MARY ANN LIEBERT, INC, 2023-09-01) -
Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project.
Taprogge, J; Leek, F; Schurrat, T; Tran-Gia, J; Vallot, D; et al. (SPRINGER, 2020-10-08)BACKGROUND: Differentiated thyroid cancer has been treated with radioiodine for almost 80 years, although controversial questions regarding radiation-related risks and the optimisation of treatment regimens remain unresolved. ... -
The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer.
Taprogge, J; Abreu, C; Yusuf, S; Ainsworth, G; Phillip, RH; et al. (SOC NUCLEAR MEDICINE INC, 2023-07-01)Radioactive iodine is well established as a successful treatment for differentiated thyroid cancer (DTC), although around 15% of patients have local recurrence or develop distant metastases and may become refractory to ...